50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
Comcast is an Asset Bonanza Priced Cheap
US stocks slip deeper into a slump as recession fears grow
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
British pound plunges to new low as tax cuts spark concern
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
Comcast is an Asset Bonanza Priced Cheap
US stocks slip deeper into a slump as recession fears grow
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
British pound plunges to new low as tax cuts spark concern
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
Comcast is an Asset Bonanza Priced Cheap
US stocks slip deeper into a slump as recession fears grow
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
British pound plunges to new low as tax cuts spark concern
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
Comcast is an Asset Bonanza Priced Cheap
US stocks slip deeper into a slump as recession fears grow
Capitalize On the $499 Billion Invested in Commercial Real Estate (Ad)pixel
British pound plunges to new low as tax cuts spark concern
Lights out, ovens off: Europe preps for winter energy crisis
NYSEAMERICAN:CPHI

China Pharma - CPHI Stock Forecast, Price & News

$0.13
-0.01 (-7.09%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.13
$0.15
50-Day Range
N/A
52-Week Range
$0.13
$0.79
Volume
183,072 shs
Average Volume
224,003 shs
Market Capitalization
$6.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CPHI stock logo

About China Pharma (NYSEAMERICAN:CPHI) Stock

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.

Receive CPHI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for China Pharma and its competitors with MarketBeat's FREE daily newsletter.

CPHI Stock News Headlines

China Pharma Posts Wider Loss In FY21
Airnov Made Its Debut at CPhI China
China Pharma Holdings
See More Headlines
Receive CPHI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for China Pharma and its competitors with MarketBeat's FREE daily newsletter.

CPHI Company Calendar

Last Earnings
8/15/2018
Today
9/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:CPHI
Previous Symbol
NYSEMKT:CPHI
Employees
237
Year Founded
N/A

Profitability

Net Income
$-2,870,000.00
Pretax Margin
-37.46%

Debt

Sales & Book Value

Annual Sales
$10.87 million
Book Value
$0.18 per share

Miscellaneous

Free Float
24,191,000
Market Cap
$6.61 million
Optionable
Not Optionable
Beta
0.25

Key Executives

  • Ms. Zhilin Li (Age 69)
    Pres, CEO, Chairman & Interim CFO
    Comp: $241.6k
  • Ms. Huang Na C.F.A.
    BOD Sec. & IR Mang.
  • Sam Hsing
    Corp. VP













CPHI Stock - Frequently Asked Questions

Are investors shorting China Pharma?

China Pharma saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 103,300 shares, a drop of 20.7% from the August 15th total of 130,200 shares. Based on an average daily volume of 323,800 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.4% of the company's stock are short sold.
View China Pharma's Short Interest
.

How were China Pharma's earnings last quarter?

China Pharma Holdings, Inc. (NYSEAMERICAN:CPHI) released its earnings results on Wednesday, August, 15th. The company reported ($0.02) earnings per share (EPS) for the quarter. The business earned $3.17 million during the quarter. China Pharma had a negative trailing twelve-month return on equity of 50.83% and a negative net margin of 37.46%.

What other stocks do shareholders of China Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other China Pharma investors own include iBio (IBIO), Biocept (BIOC), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Heat Biologics (HTBX), Jaguar Health (JAGX), NovaBay Pharmaceuticals (NBY), AbbVie (ABBV), Celsion (CLSN) and Micron Technology (MU).

What is China Pharma's stock symbol?

China Pharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CPHI."

How do I buy shares of China Pharma?

Shares of CPHI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is China Pharma's stock price today?

One share of CPHI stock can currently be purchased for approximately $0.13.

How much money does China Pharma make?

China Pharma (NYSEAMERICAN:CPHI) has a market capitalization of $6.61 million and generates $10.87 million in revenue each year. The company earns $-2,870,000.00 in net income (profit) each year or ($0.09) on an earnings per share basis.

How many employees does China Pharma have?

The company employs 237 workers across the globe.

How can I contact China Pharma?

China Pharma's mailing address is 2Nd Floor, No. 17, Jinpan Road, Haikou, HAIKOU, HAN 570216, China. The official website for the company is www.chinapharmaholdings.com. The company can be reached via phone at 8689866811730, via email at hps@chinapharmaholdings.com, or via fax at 86-898-6681-9024.

This page (NYSEAMERICAN:CPHI) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.